Clinitech Laboratory Ltd Stock Price Today (NSE: CTLLAB)
Fundamental Score
Clinitech Laboratory Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Clinitech Laboratory Ltd share price today is ₹37.80, up +0.00% on NSE/BSE as of 22 June 2026. Clinitech Laboratory Ltd (CTLLAB) is a Small-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹9.90 (Cr). The 52-week high for CTLLAB share price is ₹57.00 and the 52-week low is ₹28.55. At a P/E ratio of 21.07x, CTLLAB is currently trading below its industry average P/E of 39.28x. The company has a Return on Equity (ROE) of 5.49% and a debt-to-equity ratio of 0.02.
Clinitech Laboratory Ltd Share Price Chart — NSE/BSE Historical Performance
Clinitech Laboratory Ltd share price chart: -3.81% return over the past month. 52-week high ₹57.00, 52-week low ₹28.55.
Clinitech Laboratory Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹37.80 | ₹37.80 | ₹37.80 | ₹37.80 | 0.00 (Cr) | |
| ₹39.00 | ₹39.00 | ₹37.80 | ₹37.80 | 2.40K (Cr) | |
| ₹40.40 | ₹40.40 | ₹40.40 | ₹40.40 | 0.00 (Cr) | |
| ₹40.40 | ₹40.40 | ₹40.40 | ₹40.40 | 0.00 (Cr) | |
| ₹40.40 | ₹40.40 | ₹40.40 | ₹40.40 | 0.00 (Cr) | |
| ₹40.40 | ₹40.40 | ₹40.40 | ₹40.40 | 0.00 (Cr) | |
| ₹40.40 | ₹40.40 | ₹40.40 | ₹40.40 | 0.00 (Cr) | |
| ₹40.40 | ₹40.40 | ₹40.40 | ₹40.40 | 2.40K (Cr) | |
| ₹38.50 | ₹38.50 | ₹38.50 | ₹38.50 | 1.20K (Cr) | |
| ₹39.50 | ₹39.50 | ₹39.50 | ₹39.50 | 1.20K (Cr) |
Clinitech Laboratory Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹37.80 | ₹37.80 | ₹37.80 | ₹37.80 | +0.00% | |
| ₹41.00 | ₹41.50 | ₹37.30 | ₹37.80 | -7.80% | |
| ₹36.00 | ₹45.84 | ₹36.00 | ₹40.00 | +11.11% | |
| ₹35.35 | ₹42.24 | ₹32.20 | ₹35.00 | -0.99% | |
| ₹30.70 | ₹47.15 | ₹30.70 | ₹44.00 | +43.32% | |
| ₹41.50 | ₹43.50 | ₹28.55 | ₹34.89 | -15.93% | |
| ₹43.39 | ₹43.40 | ₹37.50 | ₹42.10 | -2.97% | |
| ₹44.64 | ₹44.64 | ₹40.00 | ₹41.90 | -6.14% | |
| ₹43.90 | ₹43.90 | ₹38.00 | ₹42.52 | -3.14% | |
| ₹50.02 | ₹57.00 | ₹41.80 | ₹46.20 | -7.64% | |
| ₹31.00 | ₹53.39 | ₹31.00 | ₹52.50 | +69.35% | |
| ₹32.70 | ₹34.95 | ₹29.15 | ₹31.00 | -5.20% |
AI Research Briefing
Powered by Gemini · 2026-04-15
Micro-cap healthcare play hinges entirely on promoter's actions; high risk, potentially high reward, liquidity a major concern.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Clinitech Laboratory changed its market maker from SVCM Securities to Kalpalabdhi Financials, effective April 10, 2026. Promoter Jagdish Umakant Nayak acquired 9,600 shares on March 30, 2026, increasing the promoter group's holding to 64.62%. This follows a series of open market purchases by the promoter in March.
CORE STORY (THE REAL GAME)
Promoter consolidation play in a micro-cap healthcare service provider. Market is betting on the promoter's ability to turn around or scale the business, or prepping it for a larger strategic move.
- Promoter stake increase signals confidence
- Healthcare sector growth provides a tailwind
- Change in market maker
- Significant order wins
- Improved financial performance
- Strategic partnerships or acquisitions
- Extreme illiquidity
- Micro-cap governance risk
- Negative free cash flow
Promoter increased stake by 0.84%
Indian healthcare sector projected for strong growth
No, Free Cash Flow 5Y: ₹-3.61 Cr
Next 3-6 months depend on promoter's actions and ability to improve financial performance. Key is revenue growth and FCF generation.
Primary Thesis Risk
Illiquidity and micro-cap governance can wipe you out.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Clinitech Laboratory Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Clinitech Laboratory Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CTLLAB across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (15.92%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 21.07 vs Industry: 39.28)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (36.36%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (24.51%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (10.14x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (62.42%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (5.49%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.15%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Negative Free Cash Flow (₹-3.61 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.32%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Clinitech Laboratory Ltd vs Healthcare Service Provider Peers
Peer Comparison - Healthcare Service Provider
Compare Clinitech Laboratory Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Clinitech Laboratory LtdClinitech Labor...Selected✓ CTLLAB • 544220 | 45.2/100 | ₹37.80₹38 | ₹9.90₹9.90 | 21.07Average 21.1 Average | 5.49%Poor 5.49% Poor | 8.15%Poor 8.15% Poor | 0.02Excellent 0.0 Excellent | — — | — — | 0.00% |
Dr Lal PathLabs LtdDr Lal PathLabs... LALPATHLAB • 539524 | 64.3/100 | ₹1617.20₹1617 | ₹25557.40₹25557.40 | 47.83Average 47.8 Average | 24.30%Excellent 24.30% Excellent | 28.88%Excellent 28.88% Excellent | 0.07Excellent 0.1 Excellent | 16.69%Excellent 16.69% Excellent | 13.09%Good 13.09% Good | 0.79% |
Vijaya Diagnostic Centre LtdVijaya Diagnost... VIJAYA • 543350 | 53.7/100 | ₹1261.40₹1261 | ₹10272.45₹10272.45 | 67.39Average 67.4 Average | 19.00%Good 19.00% Good | 20.91%Excellent 20.91% Excellent | 0.42Excellent 0.4 Excellent | 18.97%Excellent 18.97% Excellent | 15.00%Excellent 15.00% Excellent | 0.20% |
Metropolis Healthcare LtdMetropolis Heal... METROPOLIS • 542650 | 48.9/100 | ₹536.15₹536 | ₹10124.28₹10124.28 | 63.98Average 64.0 Average | 11.53%Average 11.53% Average | 14.66%Average 14.66% Average | 0.14Excellent 0.1 Excellent | -0.56%Poor -0.56% Poor | 9.22%Good 9.22% Good | 0.20% |
Thyrocare Technologies LtdThyrocare Techn... THYROCARE • 539871 | 40.5/100 | ₹512.15₹512 | ₹7724.80₹7724.80 | 60.48Average 60.5 Average | 16.15%Good 16.15% Good | 24.78%Excellent 24.78% Excellent | 0.05Excellent 0.1 Excellent | -0.64%Poor -0.64% Poor | 9.62%Good 9.62% Good | 1.44% |
Krsnaa Diagnostics LtdKrsnaa Diagnost... KRSNAA • 543328 | 39.6/100 | ₹538.45₹538 | ₹2626.09₹2626.09 | 30.73Average 30.7 Average | 9.29%Poor 9.29% Poor | 12.52%Average 12.52% Average | 0.30Excellent 0.3 Excellent | 22.05%Excellent 22.05% Excellent | 21.41%Excellent 21.41% Excellent | 0.34% |
Suraksha Diagnostic LtdSuraksha Diagno... SURAKSHA • 544293 | 47.1/100 | ₹289.60₹290 | ₹1534.08₹1534.08 | 48.05Average 48.0 Average | 16.46%Good 16.46% Good | 17.84%Good 17.84% Good | 0.51Good 0.5 Good | 16.38%Excellent 16.38% Excellent | 9.86%Good 9.86% Good | 0.00% |
3B Blackbio Diagnostics Ltd3B Blackbio Dia... 3BBLACKBIO • 532067 | 66.1/100 | ₹1225.40₹1225 | ₹1080.56₹1080.56 | 22.01Average 22.0 Average | 19.40%Good 19.40% Good | 25.75%Excellent 25.75% Excellent | 0.00Excellent 0.0 Excellent | 44.03%Excellent 44.03% Excellent | 27.29%Excellent 27.29% Excellent | 0.32% |
One Global Service Provider IncOne Global Serv... ONEGLOBAL • 514330 | 69.5/100 | ₹424.15₹424 | ₹1070.08₹1070.08 | 24.39Average 24.4 Average | 42.31%Excellent 42.31% Excellent | 56.38%Excellent 56.38% Excellent | 0.00Excellent 0.0 Excellent | 128.82%Excellent 128.82% Excellent | — — | 0.00% |
Sastasundar Ventures LtdSastasundar Ven... SASTASUNDR • 533259 | 40.3/100 | ₹313.95₹314 | ₹1042.27₹1042.27 | — — | 4.63%Poor 4.63% Poor | -1.33%Poor -1.33% Poor | 0.01Excellent 0.0 Excellent | 23.31%Excellent 23.31% Excellent | 24.47%Excellent 24.47% Excellent | 0.00% |
46.5/100 | ₹233.90₹234 | ₹826.72₹826.72 | 30.47Average 30.5 Average | 27.08%Excellent 27.08% Excellent | 28.85%Excellent 28.85% Excellent | 0.48Excellent 0.5 Excellent | — — | — — | 0.00% | |
Top Healthcare Service Provider Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Dr Lal PathLabs Ltd share price25557.40 Cr
- Vijaya Diagnostic Centre Ltd share price10272.45 Cr
- Metropolis Healthcare Ltd share price10124.28 Cr
- Thyrocare Technologies Ltd share price7724.80 Cr
- Krsnaa Diagnostics Ltd share price2626.09 Cr
Clinitech Laboratory Ltd PE Ratio History
Historical price-to-earnings ratio for CTLLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹1.63 | ₹78.86 | 48.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Clinitech Laboratory Ltd Quarterly Performance
Latest quarterly metrics for CTLLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
24.51%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
36.36%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Clinitech Laboratory Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for CTLLAB — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Clinitech Laboratory Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Clinitech Laboratory Ltd (CTLLAB) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Clinitech Laboratory Ltd
About CTLLAB (Clinitech Laboratory Ltd)
Clinitech Laboratory Ltd is a comprehensive healthcare service provider dedicated to delivering precise and reliable diagnostic solutions. With a steadfast commitment to patient we...ll-being, CTLLAB offers a wide spectrum of advanced laboratory testing, cutting-edge diagnostic imaging, and essential clinical services. Equipped with state-of-the-art technology and staffed by a team of highly skilled and experienced medical professionals, CTLLAB strives to provide timely and accurate results, empowering physicians to make informed decisions and optimize patient care. The organization's unwavering focus on quality assurance and adherence to stringent protocols ensures the highest standards of accuracy and reliability in every test and procedure performed. CTLLAB's extensive network of strategically located facilities provides convenient access to its comprehensive range of services. From routine blood tests to sophisticated molecular diagnostics, the laboratory offers a diverse menu of testing options to meet the evolving needs of its patients and healthcare partners. The diagnostic imaging centers are equipped with advanced modalities, including MRI, CT scans, ultrasound, and X-ray, enabling detailed visualization and assessment of internal structures. CTLLAB further enhances its service offering with ECG clinics, providing convenient access to essential cardiac monitoring. By integrating advanced technology with a patient-centric approach, CTLLAB is dedicated to providing accessible and high-quality healthcare services to the communities it serves. Committed to continuous improvement and innovation, Clinitech Laboratory Ltd actively invests in research and development to stay at the forefront of diagnostic advancements. The organization's robust quality management system ensures that all processes and procedures are rigorously monitored and optimized to maintain the highest standards of accuracy and reliability. CTLLAB is deeply rooted in a culture of integrity, transparency, and ethical practices, earning the trust and confidence of patients, physicians, and healthcare institutions alike. As a trusted healthcare partner, Clinitech Laboratory Ltd remains steadfast in its mission to provide exceptional diagnostic services and contribute to the well-being of the community.
Company Details
Key Leadership
CTLLAB Share Price: Frequently Asked Questions
What is the current share price of Clinitech Laboratory Ltd?
Clinitech Laboratory Ltd (CTLLAB) trades at ₹37.80 on NSE and BSE. Market cap ₹9.90 (Cr). Educational data only.
What is the P/E ratio of Clinitech Laboratory Ltd?
Clinitech Laboratory Ltd has a P/E of 21.07x vs industry average 39.28x.
What is the Bull Run score for Clinitech Laboratory Ltd?
Clinitech Laboratory Ltd has a Bull Run score of 45.2/100 based on 25+ financial parameters.
Does Clinitech Laboratory Ltd pay dividends?
Clinitech Laboratory Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Clinitech Laboratory Ltd?
Clinitech Laboratory Ltd has ROE of 5.49%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Clinitech Laboratory Ltd?
Clinitech Laboratory Ltd has debt-to-equity of 0.02.
Is Clinitech Laboratory Ltd a good investment?
Bull Run gives Clinitech Laboratory Ltd a score of 45.2/100. This is not investment advice — consult a SEBI-registered advisor.